Trial Profile

A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oplunofusp (Primary)
Indications Betacoronavirus infections; COVID 2019 infections; Enterovirus infections; Hypoxaemia; Influenza virus infections; Metapneumovirus infections; Parainfluenza virus infections
Focus Therapeutic Use
Acronyms STOP-Flu
Sponsors Ansun Biopharma

Most Recent Events

16 Aug 2023 Results published in the Clinical Infectious Diseases
08 Jul 2020 Planned initiation date changed from 1 Apr 2020 to 1 Jul 2020.
01 Apr 2020 Planned initiation date changed from 1 Mar 2020 to 1 Apr 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com